Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia

ABSTRACT: Comparison of disease stage transitions between a panel of iPSC clones derived from different MDS patients

ORGANISM(S): Homo sapiens

PROVIDER: GSE92494 | GEO | 2017/02/16

SECONDARY ACCESSION(S): PRJNA357698

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia.

Project description:We used Illumina NGS for high-throughput profiling of the DNA methylome (ERRBS) for myelodysplastic syndrome (MDS) iPSC cell lines. We performed DNA methylation analysis of the low-risk MDS1.12 cells (iPSC cell line) treated with 5-AzaC- and show that profound hypomethylation changes can be detected following treatment with 5-AzaC and support the use of our stage-specific induced pluripotent stem cells system to study mechanisms of drug action.

2017-02-17 | GSE93507 | GEO

Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.

Project description:Myeloid malignancy is increasingly viewed as a disease spectrum, comprising hematopoietic disorders that extend across a phenotypic continuum ranging from clonal hematopoiesis to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In this study, we derived a collection of induced pluripotent stem cell (iPSC) lines capturing a range of disease stages encompassing preleukemia, low-risk MDS, high-risk MDS, and secondary AML. Upon their differentiation, we found hematopoietic phenotypes of graded severity and/or stage specificity that together delineate a phenotypic roadmap of disease progression culminating in serially transplantable leukemia. We also show that disease stage transitions, both reversal and progression, can be modeled in this system using genetic correction or introduction of mutations via CRISPR/Cas9 and that this iPSC-based approach can be used to uncover disease-stage-specific responses to drugs. Our study therefore provides insight into the cellular events demarcating the initiation and progression of myeloid transformation and a new platform for testing genetic and pharmacological interventions.

| S-EPMC5337161 | biostudies-literature

Genome-wide gene expression patterns comparing various pluripotent stem cells.

Project description:Analysis of gene expression levels of whole transcripts obtained from two WA09 ES cell cultures, two dermal fibroblast cultures, two lines each for L-iPSCs, F-iPSCs and LF-iPSCs. Total RNA obtained from WA09 ESCs, the dermal fibroblasts from which all iPSCs in the microarray study were derived, two F-iPSC clones, two L-iPSC clones and two LF-iPSC clones on day 100-120 were compared.

2012-06-30 | E-GEOD-37077 | biostudies-arrayexpress

Global gene expression analysis of pluripotent cell lines and corresponding starting donor source cells

Project description:Global gene expression analysis of induced pluripotent stem cell lines and their corresponding source cells Total RNA was harvested from H9 hESC (P51), non-integrated episomal CB-iPSC clones 6.2, 6.11, 6.13, (P14), 19.11, (P11), nonviral KER-iPSC clones KA.1, KA.3 (P13) nonviral FFB-iPSC: F.1, F.6 (P14) and viral fibroblast iPSC clones IMR1 (P66), IMR4 (P64). A single sample of each condition was used for this analysis.

2012-08-23 | E-GEOD-35028 | biostudies-arrayexpress

CD44 is a negative cell surface marker for pluripotent stem cell identification during human fibroblast reprogramming

Project description:Analysis of different iPSC clones in comparison to parental fibroblasts and Pluripotent ESC and iPSC lines Total RNA obtained from iPSC clones generated with CytoTune reprogramming of BJ Fbiroblasts and compared to parent BJ fibroblasts and known pluripotent H9 ESC and Gibco Episomal iPSC lines.

2013-11-05 | E-GEOD-51980 | biostudies-arrayexpress

Expression data from Myotonic dystrophy type 1 (DM1) patient-derived induced pluripotent cell

Project description:DM1-iPSCs were generated from the peripheral blood of male adult patients. All clones were generated using episomal vectors. For skeletal muscle differentiation of the DM1-iPSCs, tet-on MYOD1 expression vector was transfected into DM1-iPSCs. To examine whether DM1-iPSC clones with different repeat sizes have acquired different characteristics, we isolated DM1-iPSC clones with different repeat sizes. We isolated 2 clones (S45 and S118) showing repeat size of 400~900, 2 clones (S14 and S24) showing repeat size of 1200~1600, and 2 clones (S1 and S16) showing repeat size of 1800~2800.

2024-12-16 | GSE214626 | GEO

CD44 is a negative cell surface marker for pluripotent stem cell identification during human fibroblast reprogramming

Project description:Analysis of different iPSC clones in comparison to parental fibroblasts and Pluripotent ESC and iPSC lines

2013-11-05 | GSE51980 | GEO

Gene expression profiles of familial Alzheimer's disease with presenilin 2 mutation patient-specific induced pluripotent stem cells

Project description:We established two clones of induced pluripotent stem cells (iPSC) with the presenilin 2 mutation, N141 (PS2-1 iPSC and PS2-2 iPSC) by retroviral transduction of primary human fibroblasts. To show the similarity among 201B7 iPSC, PD01-25 iPSC(Sporadic Parkinson's disease patient derived iPSC), PS2-1 iPSC, PS2-2 iPSC, this experiment was designed.

2011-09-10 | GSE28379 | GEO

Targeting IRAK1 as a therapeutic approach for Myelodysplastic Syndrome

Project description:Myelodysplastic Syndromes (MDS) result from expansion of defective hematopoietic stem/progenitor clones. There is an urgent need to develop targeted therapies capable of eliminating the defective MDS clones. We identified that IRAK1, an immune modulating kinase, is overexpressed and hyperactivated in MDS. MDS-propagating clones treated with a small-molecule IRAK1 inhibitor (IRAK1/4-Inh) exhibited impaired expansion and increased apoptosis, which coincided with TRAF6/NF-κB inhibition. Suppression of IRAK1, either by RNAi or with IRAK1/4-Inh, is selectively detrimental to MDS clones as normal CD34+ cells are preserved. Based on conclusions derived from an integrative gene expression analysis, we combined IRAK1 and BCL2 inhibitors and found that co-treatment collaboratively and selectively eliminated MDS clones. In summary, these findings implicate IRAK1 as a drugable target in MDS.

2013-04-25 | GSE46346 | GEO

Gene expression profiles of familial Alzheimer's disease with presenilin 2 mutation patient-specific induced pluripotent stem cells

2011-09-09 | E-GEOD-28379 | biostudies-arrayexpress